Everolimus after liver cancer surgery
Part of Cancer clinical trials.
This trial tests whether the drug everolimus can help prevent liver cancer from coming back after surgery. It is for people with high-risk liver cancer who have had their tumor completely removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had surgery to completely remove a liver tumor.
- Your liver cancer is considered high-risk for coming back.
- You have not taken everolimus or similar drugs before.
- You do not have severe kidney, heart, or blood problems.
- You are not pregnant, breastfeeding, or planning pregnancy during the study.
- You do not have other active cancers or serious medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether everolimus, a transplant medicine, can safely reduce the chance that liver cancer comes back after liver transplant. It compares how well the treatment works while carefully monitoring side effects and safety.
This trial tests if switching from a standard anti-rejection medicine to everolimus is safe and effective for liver transplant patients. It may help protect kidney function while preventing organ rejection.
This Phase 2 trial tests whether adding everolimus to standard first-line hormone (endocrine) therapy can better control a certain type of advanced breast cancer. It is designed for people whose tumor matches a specific “SNF1 subtype.”
This trial tests whether adding everolimus to the usual treatment helps people with advanced (stage III inoperable or stage IV) gallbladder cancer live longer and control the disease better. You may be eligible if you have not had prior treatment for the advanced cancer, and your blood tests and organ functions are in safe ranges.
This trial tests the combination of everolimus (a targeted pill) with a PD-1 immunotherapy drug for people with advanced colorectal cancer that has a specific gene change (PTEN mutation). The goal is to see if this two-drug approach works better than standard treatments for cancers that have stopped responding to chemotherapy.
This trial tests the drug Everolimus for people with a specific type of advanced colorectal cancer (CDK12-deficient) that has progressed after standard treatments. The goal is to see if Everolimus can help shrink or control the cancer.
Hear when a new Carcinom trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.